Hormonal
Subcutaneous semaglutide (up to 2.4 mg weekly) produces a mean weight reduction of 11.85% in adults with obesity without diabetes compared to placebo, though it significantly increases the risk of gastrointestinal adverse events and treatment discontinuation.
If you have obesity without diabetes, semaglutide (up to 2.4 mg weekly) can help you lose about 12% of your body weight, which is significantly more than placebo. However, you must be prepared for a high likelihood of temporary stomach issues like nausea or diarrhea. These side effects are common but usually mild and go away. You will also need to follow a reduced-calorie diet and exercise plan alongside the medication for best results.
The mean difference for weight reduction was -11.85%, favoring semaglutide... Secondary outcomes showed that the risk of developing gastrointestinal adverse events was 1.59 times more likely with semaglutide... Risk for discontinuation due to adverse events was twice as likely in the semaglutide group... Serious events were mostly of gastrointestinal and hepatobiliary disorders such as acute pancreatitis and cholelithiasis.
Why this rating
Based on a systematic review and meta-analysis of 4 RCTs with 3,613 participants, though heterogeneity was noted in some outcomes.
Source
Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis
Hanna Clementine Tan et al. · Journal of the ASEAN Federation of Endocrine Societies · 2022
DOI 10.15605/jafes.037.02.14
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →